{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T14:03:54Z","timestamp":1794492234716,"version":"4.9.1"},"reference-count":112,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2021.9693","type":"journal-article","created":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T10:03:39Z","timestamp":1611569019000},"source":"Crossref","is-referenced-by-count":58,"title":["Multifactorial expression of IL\u20116 with update on COVID\u201119 and the therapeutic strategies of its blockade (Review)"],"prefix":"10.3892","volume":"21","author":[{"given":"Elena","family":"Niculet","sequence":"first","affiliation":[{"name":"Department of Morphological and Functional Sciences, Faculty of Medicine and Pharmacy, \u2018Dunarea de Jos\u2019 University, 800010 Galati, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Chioncel","sequence":"additional","affiliation":[{"name":"Cardio\u2011Thoracic Department, \u2018Carol Davila\u2019 University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Elisei","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Faculty of Medicine and Pharmacy, \u2018Dun\u0103rea de Jos\u2019 University, 800010 Galati, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Miulescu","sequence":"additional","affiliation":[{"name":"Department of Morphological and Functional Sciences, Faculty of Medicine and Pharmacy, \u2018Dunarea de Jos\u2019 University, 800010 Galati, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olimpia","family":"Buzia","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Faculty of Medicine and Pharmacy, \u2018Dun\u0103rea de Jos\u2019 University, 800010 Galati, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Nwabudike","sequence":"additional","affiliation":[{"name":"Department of Diabetic Foot Care, \u2018Prof.\u00a0N.\u00a0Paulescu\u2019 National Institute of Diabetes, 011233 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Craescu","sequence":"additional","affiliation":[{"name":"Department of Morphological and Functional Sciences, Faculty of Medicine and Pharmacy, \u2018Dunarea de Jos\u2019 University, 800010 Galati, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miruna","family":"Draganescu","sequence":"additional","affiliation":[{"name":"Clinical Department, Faculty of Medicine and Pharmacy, \u2018Dunarea de Jos\u2019 University, 800010 Galati, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florin","family":"Bujoreanu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, \u2018Sf.\u00a0Cuvioasa Parascheva\u2019 Clinical Hospital of Infectious Diseases, 800179 Galati, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeta","family":"Marinescu","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Faculty of Medicine and Pharmacy, \u2018Dun\u0103rea de Jos\u2019 University, 800010 Galati, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Arbune","sequence":"additional","affiliation":[{"name":"Centre of Medical\u2011Pharmaceutical Research, \u2018Dun\u0103rea de Jos\u2019 University, 800010 Galati, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Radaschin","sequence":"additional","affiliation":[{"name":"Research Center in The Field of Medical and Pharmaceutical Sciences, ReFORM\u2011UDJ, \u2018Dun\u0103rea de Jos\u2019 University, 800010 Galati, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Bobeica","sequence":"additional","affiliation":[{"name":"Department of Dermato\u2011Venereology, Doctoral School, University of Medicine and Pharmacy \u2018Gr. T. Popa\u2019, 700115 Ia\u0219i, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurel","family":"Nechita","sequence":"additional","affiliation":[{"name":"Department of Morphological and Functional Sciences, Faculty of Medicine and Pharmacy, \u2018Dunarea de Jos\u2019 University, 800010 Galati, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alin","family":"Tatu","sequence":"additional","affiliation":[{"name":"Research Center in The Field of Medical and Pharmaceutical Sciences, ReFORM\u2011UDJ, \u2018Dun\u0103rea de Jos\u2019 University, 800010 Galati, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2021,1,25]]},"reference":[{"key":"key20220302134039_b1-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.bbrc.2019.07.044","article-title":"Interleukin-6 (IL-6) mediates protection against glucose toxicity in human M\u00fcller cells via activation of VEGF-A signaling","volume":"517","author":"Coughlin","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"key":"key20220302134039_b2-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2016.07.006","article-title":"Revisiting IL-6 antagonism in multiple myeloma","volume":"105","author":"Matthes","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"issue":"576969","key":"key20220302134039_b3-ETM-0-0-09693","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2019.576969","article-title":"Imiquimod and interferon-alpha augment monocyte-mediated astrocyte secretion of MCP-1, IL-6 and IP-10 in a human co-culture system","volume":"333","author":"Rizzo","year":"2019","journal-title":"J Neuroimmunol"},{"key":"key20220302134039_b4-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.cyto.2018.06.022","article-title":"Hypoxia regulates angeogenic-osteogenic coupling process via up-regulating IL-6 and IL-8 in human osteoblastic cells through hypoxia-inducible factor-1\u03b1 pathway","volume":"113","author":"Niu","year":"2019","journal-title":"Cytokine"},{"issue":"115327","key":"key20220302134039_b5-ETM-0-0-09693","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2020.115327","article-title":"A panoramic review of IL-6: Structure, pathophysiological roles and inhibitors","volume":"28","author":"Kaur","year":"2020","journal-title":"Bioorg Med Chem"},{"key":"key20220302134039_b6-ETM-0-0-09693","first-page":"S1","article-title":"Interleukin-6 as a multifunctional regulator: Inflammation, immune response, and fibrosis","volume":"2 (Suppl 2)","author":"Choy","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"key20220302134039_b7-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.bbamcr.2011.01.034","article-title":"The pro- and anti-inflammatory properties of the cytokine interleukin-6","volume":"1813","author":"Scheller","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"key20220302134039_b8-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cyto.2018.11.023","article-title":"Therapeutic blockade of the interleukin-6 receptor (IL-6R) allows sIL-6R generation by proteolytic cleavage","volume":"114","author":"Prenissl","year":"2019","journal-title":"Cytokine"},{"key":"key20220302134039_b9-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.bbrc.2018.09.042","article-title":"Skeletal muscle secretion of IL-6 is muscle type specific: Ex vivo evidence","volume":"505","author":"Liang","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"key20220302134039_b10-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"S86","DOI":"10.1016\/j.jcot.2019.09.014","article-title":"Can IL-6 predict the development of fat embolism in polytrauma? A rabbit model pilot experimental study","volume":"11 (Suppl 1)","author":"Karthick","year":"2020","journal-title":"J Clin Orthop Trauma"},{"key":"key20220302134039_b11-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.bbi.2018.02.013","article-title":"Rethinking IL-6 and CRP: Why they are more than inflammatory biomarkers, and why it matters","volume":"70","author":"Del Giudice","year":"2018","journal-title":"Brain Behav Immun"},{"key":"key20220302134039_b12-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.nlm.2018.06.006","article-title":"IL-6 deficiency alters spatial memory in 4- and 24-month-old mice","volume":"155","author":"Bialuk","year":"2018","journal-title":"Neurobiol Learn Mem"},{"issue":"103629","key":"key20220302134039_b13-ETM-0-0-09693","doi-asserted-by":"publisher","DOI":"10.1016\/j.dci.2020.103629","article-title":"Molecular and functional characterization of IL-6 receptor (IL-6R) and glycoprotein 130 (gp130) in Nile tilapia (Oreochromis niloticus)","volume":"106","author":"Zhou","year":"2020","journal-title":"Dev Comp Immunol"},{"key":"key20220302134039_b14-ETM-0-0-09693","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cophys.2019.03.009","article-title":"Exercise and health-emerging roles of IL-6","volume":"10","author":"Ellingsgaard","year":"2019","journal-title":"Curr Opin Physiol"},{"key":"key20220302134039_b15-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.cytogfr.2018.04.004","article-title":"IL-6 family cytokines: Key inflammatory mediators as biomarkers and potential therapeutic targets","volume":"41","author":"Unver","year":"2018","journal-title":"Cytokine Growth Factor Rev"},{"issue":"116602","key":"key20220302134039_b16-ETM-0-0-09693","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2019.116602","article-title":"Ingested ACTH blocks Th17 production by inhibiting GALT IL-6","volume":"409","author":"Dittel","year":"2020","journal-title":"J Neurol Sci"},{"key":"key20220302134039_b17-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.biopha.2018.09.067","article-title":"PMA treated THP-1-derived-IL-6 promotes EMT of SW48 through STAT3\/ERK-dependent activation of Wnt\/\u03b2-catenin signaling pathway","volume":"108","author":"Gao","year":"2018","journal-title":"Biomed Pharmacother"},{"issue":"102991","key":"key20220302134039_b18-ETM-0-0-09693","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2019.102991","article-title":"Structure-based design and synthesis of new 4-methylcoumarin-based lignans as pro-inflammatory cytokines (TNF-\u03b1, IL-6 and IL-1\u03b2) inhibitors","volume":"89","author":"Santhosh Kumar","year":"2019","journal-title":"Bioorg Chem"},{"key":"key20220302134039_b19-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1111\/jdv.15166","article-title":"Rosacea-like demodicosis (but not primary demodicosis) and papulopustular rosacea may be two phenotypes of the same disease-a microbioma, therapeutic and diagnostic tools perspective","volume":"33","author":"Tatu","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key20220302134039_b20-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"e497","DOI":"10.1097\/MJT.0000000000000581","article-title":"Contact allergy to topical mometasone furoate confirmed by rechallenge and patch test","volume":"25","author":"Tatu","year":"2018","journal-title":"Am J Ther"},{"key":"key20220302134039_b21-ETM-0-0-09693","first-page":"25","article-title":"Clinical, laboratory and therapeutic profile of lichen planus","volume":"121","author":"Br\u0103ni\u0219teanu","year":"2017","journal-title":"Rev Med Chir Soc Med Nat"},{"issue":"4270","key":"key20220302134039_b22-ETM-0-0-09693","article-title":"Piperine-a major principle of black pepper: A review of its bioactivity and studies","volume":"9","author":"Stojanovi\u0107-Radi\u0107","year":"2019","journal-title":"Appl Sci"},{"key":"key20220302134039_b23-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.3892\/etm.2018.6977","article-title":"New insights in vitiligo treatments using bioactive compounds from Piper nigrum","volume":"17","author":"Mih\u0103il\u0103","year":"2019","journal-title":"Exp Ther Med"},{"key":"key20220302134039_b24-ETM-0-0-09693","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.37358\/RC.18.8.6484","article-title":"Hydrochlorothiazide: Chemical structure, therapeutic, phototoxic and carcinogenetic effects in dermatology","volume":"69","author":"Tatu","year":"2018","journal-title":"Rev Chim (Bucharest)"},{"key":"key20220302134039_b25-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/jidsymp.2011.9","article-title":"Rosacea: The cytokine and chemokine network","volume":"15","author":"Gerber","year":"2011","journal-title":"J Investig Dermatol Symp Proc"},{"key":"key20220302134039_b26-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/s0026-0495(00)90563-8","article-title":"Effects of hydrochlorothiazide and furosemide diuretics on human bone marrow stromal osteoprogenitor cells","volume":"49","author":"Kim","year":"2000","journal-title":"Metabolism"},{"key":"key20220302134039_b27-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"571","DOI":"10.3892\/br.2017.887","article-title":"Identifying the association between interleukin-6 and lichen planus: A meta-analysis","volume":"6","author":"Yin","year":"2017","journal-title":"Biomed Rep"},{"key":"key20220302134039_b28-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/j.1601-0825.2011.01867.x","article-title":"Interleukin-6 in oral diseases: A review","volume":"18","author":"Nibali","year":"2012","journal-title":"Oral Dis"},{"key":"key20220302134039_b29-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"12","DOI":"10.4103\/0019-5154.92668","article-title":"Serum concentration of IL-6, IL-2, TNF-\u03b1, and IFN\u03b3 in vitiligo patients","volume":"57","author":"Singh","year":"2012","journal-title":"Indian J Dermatol"},{"issue":"916497","key":"key20220302134039_b30-ETM-0-0-09693","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/916497","article-title":"Cytokines and chemokines in irritant contact dermatitis","volume":"2013","author":"Lee","year":"2013","journal-title":"Mediators Inflamm"},{"issue":"103961","key":"key20220302134039_b31-ETM-0-0-09693","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2019.103961","article-title":"Lipopolysaccharide enhances human herpesvirus 1 replication and IL-6 release in epithelial cells","volume":"140","author":"Zeng","year":"2020","journal-title":"Microb Pathog"},{"key":"key20220302134039_b32-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1016\/j.celrep.2019.01.104","article-title":"Influenza vaccination induces NK-cell-mediated type-II IFN response that regulates humoral immunity in an IL-6-dependent manner","volume":"26","author":"Farsakoglu","year":"2019","journal-title":"Cell Rep"},{"key":"key20220302134039_b33-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.micinf.2017.08.007","article-title":"IL-6-mediated signaling pathways limit chlamydia muridarum infection and exacerbate its pathogenicity in the mouse genital tract","volume":"19","author":"Sun","year":"2017","journal-title":"Microbes Infect"},{"key":"key20220302134039_b34-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.ijpara.2018.05.011","article-title":"IL-6 is required for protective immune responses against early filarial infection","volume":"48","author":"Muhsin","year":"2018","journal-title":"Int J Parasitol"},{"key":"key20220302134039_b35-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1046\/j.1464-2662.2001.00096.x","article-title":"Levels of IL-6 and soluble IL-6 receptor are increased in HIV patients with a history of immune restoration disease after HAART","volume":"3","author":"Stone","year":"2002","journal-title":"HIV Med"},{"key":"key20220302134039_b36-ETM-0-0-09693","doi-asserted-by":"crossref","first-page":"175","DOI":"10.37358\/MP.17.1.4811","article-title":"Clinical personality patterns in young adults with HIV nosocomial infection from the region of southeast Romania","volume":"54","author":"Modrigan","year":"2017","journal-title":"Mater Plast"},{"key":"key20220302134039_b37-ETM-0-0-09693","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.37358\/RC.17.5.5625","article-title":"Resistence profile of the isolated bacterial stems in invasive infections in three hospitals from the south-east of Romania","volume":"68","author":"Tiutiuca","year":"2017","journal-title":"Rev Chim (Bucharest)"},{"key":"key20220302134039_b38-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.bbrc.2018.09.173","article-title":"Real-time monitoring of IL-6 and IL-10 reporter expression for anti-inflammation activity in live RAW 264.7 cells","volume":"505","author":"Saiki","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"key20220302134039_b39-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.bbrc.2017.11.067","article-title":"Endothelial Robo4 regulates IL-6 production by endothelial cells and monocytes via a crosstalk mechanism in inflammation","volume":"495","author":"Shirakura","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"key20220302134039_b40-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.cyto.2016.11.006","article-title":"IL-6 trans-signaling is another pathway to upregulate osteopontin","volume":"90","author":"Uchibori","year":"2017","journal-title":"Cytokine"},{"issue":"104402","key":"key20220302134039_b41-ETM-0-0-09693","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104402","article-title":"Il-6 involvement in pain, fatigue and mood disorders in rheumatoid arthritis and the effects of Il-6 inhibitor sarilumab","volume":"149","author":"Atzeni","year":"2019","journal-title":"Pharmacol Res"},{"key":"key20220302134039_b42-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.clineuro.2018.10.004","article-title":"Significant association of IL-6-572G\/C, IL-6-597G\/A, and IL-6-174G\/C polymorphisms and susceptibility to lumbar degenerative disease: A meta-analysis","volume":"175","author":"Gao","year":"2018","journal-title":"Clin Neurol Neurosurg"},{"key":"key20220302134039_b43-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nature05487","article-title":"Mechanisms linking obesity with cardiovascular disease","volume":"444","author":"Van Gaal","year":"2006","journal-title":"Nature"},{"key":"key20220302134039_b44-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00011-009-0060-4","article-title":"The major inflammatory mediator interleukin-6 and obesity","volume":"58","author":"Eder","year":"2009","journal-title":"Inflamm Res"},{"key":"key20220302134039_b45-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1161\/ATVBAHA.108.179705","article-title":"Inflammation in atherosclerosis","volume":"32","author":"Libby","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key20220302134039_b46-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/S0140-6736(11)61931-4","article-title":"Interleukin-6 receptor pathways in coronary heart disease: A collaborative meta-analysis of 82 studies","volume":"379","author":"Sarwar","year":"2012","journal-title":"Lancet"},{"key":"key20220302134039_b47-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/S0140-6736(12)60110-X","article-title":"The interleukin-6 receptor as a target for prevention of coronary heart disease: A mendelian randomisation analysis","volume":"379","author":"Swerdlow","year":"2012","journal-title":"Lancet"},{"key":"key20220302134039_b48-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1210\/jcem.86.3.7305","article-title":"Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women","volume":"86","author":"Fernandez-Real","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"key20220302134039_b49-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0140-6736(09)61717-7","article-title":"C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: An individual participant meta-analysis","volume":"375","author":"Kaptoge","year":"2010","journal-title":"Lancet"},{"key":"key20220302134039_b50-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/CRD.0000000000000021","article-title":"Inflammation and atherosclerosis: A review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy","volume":"22","author":"Hartman","year":"2014","journal-title":"Cardiol Rev"},{"key":"key20220302134039_b51-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1161\/01.ATV.0000079512.66448.1D","article-title":"C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: The PRIME study","volume":"23","author":"Luc","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key20220302134039_b52-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.amjmed.2007.06.030","article-title":"Biomarkers to predict recurrent cardiovascular disease: The heart and soul study","volume":"121","author":"Shlipak","year":"2008","journal-title":"Am J Med"},{"key":"key20220302134039_b53-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0034218","article-title":"Association between serum interleukin-6 concentrations and mortality in older adults: The Rancho Bernardo study","volume":"7","author":"Lee","year":"2012","journal-title":"PLoS One"},{"issue":"42","key":"key20220302134039_b54-ETM-0-0-09693","article-title":"Interleukin-6 is stronger associated with all-cause and cardiovascular mortality than C-reactive protein, serum amyloid and fibrinogen (the luric study)","volume":"11","author":"Scharnagl","year":"2010","journal-title":"Atheroscler Suppl"},{"key":"key20220302134039_b55-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s12013-011-9209-1","article-title":"Interleukin-6, but not soluble adhesion molecules, predicts a subsequent mortality from cardiovascular disease in patients with acute ST-segment elevation myocardial infarction","volume":"61","author":"Fan","year":"2011","journal-title":"Cell Biochem Biophys"},{"key":"key20220302134039_b56-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.jjcc.2008.12.007","article-title":"Inflammatory biomarkers in coronary artery disease","volume":"53","author":"Zakynthinos","year":"2009","journal-title":"J Cardiol"},{"key":"key20220302134039_b57-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/s0021-9150(99)00463-3","article-title":"Inflammation, obesity, stress and coronary heart disease: Is interleukin-6 the link?","volume":"148","author":"Yudkin","year":"2000","journal-title":"Atherosclerosis"},{"key":"key20220302134039_b58-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cyto.2014.12.024","article-title":"The varying faces of IL-6: From cardiac protection to cardiac failure","volume":"74","author":"Fontes","year":"2015","journal-title":"Cytokine"},{"key":"key20220302134039_b59-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s11357-010-9165-5","article-title":"Systemic inflammation (interleukin 6) predicts all cause mortality in men: Results from a 9-year follow-up of the MEMO study","volume":"33","author":"Baune","year":"2011","journal-title":"Age (Dordr)"},{"key":"key20220302134039_b60-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.amjcard.2006.01.045","article-title":"Interleukin-6 and the risk of future cardiovascular events in patients with angina pectoris and\/or healed myocardial infarction","volume":"98","author":"Fisman","year":"2006","journal-title":"Am J Cardiol"},{"key":"key20220302134039_b61-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/S0140-6736(12)61246-X","article-title":"The interleukin-6 pathway and atherosclerosis","volume":"379","author":"Boekholdt","year":"2012","journal-title":"Lancet"},{"key":"key20220302134039_b62-ETM-0-0-09693","first-page":"3","article-title":"The role of interleukin-6 in cases of cardiac myxoma. Clinical features, immunologic abnormalities, and a possible role in recurrence","volume":"28","author":"Mendoza","year":"2001","journal-title":"Tex Heart Inst J"},{"key":"key20220302134039_b63-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1161\/01.hyp.38.3.399","article-title":"Blood pressure and inflammation in apparently healthy men","volume":"38","author":"Chae","year":"2001","journal-title":"Hypertension"},{"issue":"e78","key":"key20220302134039_b64-ETM-0-0-09693","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050078","article-title":"Long-term interleukin-6 levels and subsequent risk of coronary heart disease: Two new prospective studies and a systematic review","volume":"5","author":"Danesh","year":"2008","journal-title":"PLoS Med"},{"key":"key20220302134039_b65-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1161\/01.cir.103.7.947","article-title":"Cardiovascular disease, interleukin-6, and risk of mortality in older women: The women's health and aging study","volume":"103","author":"Volpato","year":"2001","journal-title":"Circulation"},{"key":"key20220302134039_b66-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1053\/j.ajkd.2004.09.018","article-title":"Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients","volume":"45","author":"Rao","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"key20220302134039_b67-ETM-0-0-09693","first-page":"19","article-title":"Increased interleukin-6 but not tumour necrosis factor-alpha predicts mortality in the population of elderly heart failure patients","volume":"13","author":"Haugen","year":"2008","journal-title":"Exp Clin Cardiol"},{"key":"key20220302134039_b68-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1093\/ndt\/gfh052","article-title":"Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients","volume":"19","author":"Panichi","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"key20220302134039_b69-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1196\/annals.1386.051","article-title":"Immunogenetics, gender, and longevity","volume":"1089","author":"Candore","year":"2006","journal-title":"Ann NY Acad Sci"},{"key":"key20220302134039_b70-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nrcardio.2014.28","article-title":"The inflammatory response in myocardial injury, repair, and remodelling","volume":"11","author":"Frangogiannis","year":"2014","journal-title":"Nat Rev Cardiol"},{"key":"key20220302134039_b71-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1007\/s00392-018-1387-z","article-title":"Plasma interleukin 6 levels are associated with cardiac function after ST-elevation myocardial infarction","volume":"108","author":"Groot","year":"2019","journal-title":"Clin Res Cardiol"},{"key":"key20220302134039_b72-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1161\/ATVBAHA.110.208785","article-title":"C-reactive protein, interleukin 6, fibrinogen and risk of sudden death in European middle-aged men: The PRIME study","volume":"30","author":"Empana","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"A15693","key":"key20220302134039_b73-ETM-0-0-09693","article-title":"Genetic deletion of interleukin-6 attenuates left ventricular dysfunction and remodeling after a reperfused myocardial infarction","volume":"130 (Suppl 2)","author":"Samanta","year":"2014","journal-title":"Circulation"},{"key":"key20220302134039_b74-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1161\/STROKEAHA.113.002289","article-title":"High-sensitivity C-reactive protein and interleukin-6-dominant inflammation and ischemic stroke risk: The northern Manhattan study","volume":"45","author":"Luna","year":"2014","journal-title":"Stroke"},{"issue":"e005038","key":"key20220302134039_b75-ETM-0-0-09693","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.005038","article-title":"Interleukin 6 inhibition and coronary artery disease in a high risk population: A prospective community based clinical study","volume":"6","author":"Bacchiega","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"key20220302134039_b76-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1093\/eurheartj\/ehv759","article-title":"In\ufb02ammatory cytokines in atherosclerosis: Current therapeutic approaches","volume":"37","author":"Tousoulis","year":"2016","journal-title":"Eur Heart J"},{"key":"key20220302134039_b77-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1111\/bph.13818","article-title":"Targeting in\ufb02ammation to reduce cardiovascular disease risk: A realistic clinical prospect?","volume":"174","author":"Welsh","year":"2017","journal-title":"Br J Pharmacol"},{"key":"key20220302134039_b78-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/ard.2008.105197","article-title":"Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The Ambition study","volume":"69","author":"Jones","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key20220302134039_b79-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomized trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"key":"key20220302134039_b80-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1136\/annrheumdis-2015-207872","article-title":"Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis","volume":"75","author":"Gabay","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"key20220302134039_b81-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","article-title":"Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): A randomised, double-blind, controlled phase 4 trial","volume":"381","author":"Gabay","year":"2013","journal-title":"Lancet"},{"key":"key20220302134039_b82-ETM-0-0-09693","doi-asserted-by":"crossref","first-page":"S505.1","DOI":"10.1136\/annrheumdis-2016-eular.4032","article-title":"FRI0204 effect of tocilizumab treatment on QTc interval in patients with rheumatoid arthritis without cardiac symptoms","volume":"75 (Suppl 2)","author":"Yokoe","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"A160","key":"key20220302134039_b83-ETM-0-0-09693","article-title":"OP0313 effect of tocilizumab on left ventricular function assessed using a comprehensive cardiac magnetic resonance approach in rheumatoid arthritis patients without cardiac symptoms","volume":"72 (Suppl 3)","author":"Kobayashi","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20220302134039_b84-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/j.1477-2574.2010.00289.x","article-title":"Gut and liver handling of interleukin-6 during liver resection in man","volume":"13","author":"Dello","year":"2011","journal-title":"HPB (Oxford)"},{"key":"key20220302134039_b85-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.advms.2015.01.008","article-title":"Serum levels of HGF, IL-6, and TGF-\u03b1 after benign liver tumor resection","volume":"60","author":"Kornasiewicz","year":"2015","journal-title":"Adv Med Sci"},{"key":"key20220302134039_b86-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.bbalip.2018.12.003","article-title":"Caffeine-stimulated muscle IL-6 mediates alleviation of non-alcoholic fatty liver disease","volume":"1864","author":"Fang","year":"2019","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"key20220302134039_b87-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.cyto.2004.03.019","article-title":"Orally administered IL-6 induces elevated intestinal GM-CSF gene expression and splenic CFU-GM","volume":"27","author":"Rollwagen","year":"2004","journal-title":"Cytokine"},{"key":"key20220302134039_b88-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ccr.2009.01.001","article-title":"IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer","volume":"15","author":"Grivennikov","year":"2009","journal-title":"Cancer Cell"},{"key":"key20220302134039_b89-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.smim.2013.12.003","article-title":"Master regulator of intestinal disease: IL-6 in chronic inflammation and cancer development","volume":"26","author":"Waldner","year":"2014","journal-title":"Semin Immunol"},{"issue":"56","key":"key20220302134039_b90-ETM-0-0-09693","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2018.00056","article-title":"Underlying causes and therapeutic targeting of the inflammatory tumor microenvironment","volume":"6","author":"Comen","year":"2018","journal-title":"Front Cell Dev Biol"},{"key":"key20220302134039_b91-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.cmet.2011.12.004","article-title":"IL-6 muscles in on the gut and pancreas to enhance insulin secretion","volume":"15","author":"Allen","year":"2012","journal-title":"Cell Metab"},{"key":"key20220302134039_b92-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jmii.2015.03.002","article-title":"Polymorphisms of the IL-6, IL-8 and IL-10 genes and the risk of gastric pathology in patients infected with Helicobacter pylori","volume":"50","author":"Ramis","year":"2017","journal-title":"J Microbiol Immunol Infect"},{"key":"key20220302134039_b93-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.cmet.2018.04.008","article-title":"Interleukin-6 delays gastric emptying in humans with direct effects on glycemic control","volume":"27","author":"Lang Lehrskov","year":"2018","journal-title":"Cell Metab"},{"key":"key20220302134039_b94-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.canlet.2018.01.017","article-title":"MUC16 C terminal-induced secretion of tumor-derived IL-6 contributes to tumor-associated Treg enrichment in pancreatic cancer","volume":"418","author":"Fan","year":"2018","journal-title":"Cancer Lett"},{"key":"key20220302134039_b95-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.imbio.2009.07.003","article-title":"IL-6-transfected tumor cells modulate the status of CD8(+) and CD4(+) T cells to control tumor growth","volume":"215","author":"Hsieh","year":"2010","journal-title":"Immunobiology"},{"key":"key20220302134039_b96-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.bbrc.2013.04.102","article-title":"The expression of IL-6 and STAT3 might predict progression and unfavorable prognosis in Wilms' tumor","volume":"435","author":"Zhang","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"issue":"111447","key":"key20220302134039_b97-ETM-0-0-09693","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2019.05.028","article-title":"Heterotypic cell-in-cell structures in colon cancer can be regulated by IL-6 and lead to tumor immune escape","volume":"382","author":"Wang","year":"2019","journal-title":"Exp Cell Res"},{"key":"key20220302134039_b98-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.yexcr.2018.03.025","article-title":"Hypoxia-induced HMGB1 expression of HCC promotes tumor invasiveness and metastasis via regulating macrophage-derived IL-6","volume":"367","author":"Jiang","year":"2018","journal-title":"Exp Cell Res"},{"key":"key20220302134039_b99-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.smim.2014.01.008","article-title":"The two faces of IL-6 in the tumor microenvironment","volume":"26","author":"Fisher","year":"2014","journal-title":"Semin Immunol"},{"issue":"105982","key":"key20220302134039_b100-ETM-0-0-09693","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105982","article-title":"Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies","volume":"55","author":"Zhao","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"key20220302134039_b101-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1016\/j.jinf.2020.04.005","article-title":"Saliva is a reliable tool to detect SARS-CoV-2","volume":"81","author":"Azzi","year":"2020","journal-title":"J Infect"},{"key":"key20220302134039_b102-ETM-0-0-09693"},{"key":"key20220302134039_b103-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/jmv.25801","article-title":"Tocilizumab treatment in COVID-19: A single center experience","volume":"92","author":"Luo","year":"2020","journal-title":"J Med Virol"},{"issue":"105954","key":"key20220302134039_b104-ETM-0-0-09693","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105954","article-title":"The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality","volume":"55","author":"Zhang","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"102452","key":"key20220302134039_b105-ETM-0-0-09693","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102452","article-title":"Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?","volume":"111","author":"Liu","year":"2020","journal-title":"J Autoimmun"},{"key":"key20220302134039_b106-ETM-0-0-09693","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/conmed-2018-000003","article-title":"Targeting IL-6: A review of data","volume":"2","author":"Smolen","year":"2018","journal-title":"Considerations Med"},{"key":"key20220302134039_b107-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.exer.2018.09.009","article-title":"Inhibition of interleukin-6 trans-signaling prevents inflammation and endothelial barrier disruption in retinal endothelial cells","volume":"178","author":"Valle","year":"2019","journal-title":"Exp Eye Res"},{"key":"key20220302134039_b108-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1136\/annrheumdis-2013-204405","article-title":"Sarilumab, a fully human monoclonal antibody against IL-6R\u03b1 in patients with rheumatoid arthritis and an inadequate response to methotrexate: Efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial","volume":"73","author":"Huizinga","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20220302134039_b109-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1136\/annrheumdis-2013-205002","article-title":"IL-6 targeting compared to TNF targeting in rheumatoid arthritis: Studies of olokizumab, sarilumab and sirukumab","volume":"73","author":"Tanaka","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20220302134039_b110-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/cpdd.121","article-title":"Safety and pharmacokinetics of olokizumab, an anti-IL-6 monoclonal antibody, administered to healthy male volunteers: A randomized phase I study","volume":"3","author":"Kretsos","year":"2014","journal-title":"Clin Pharmacol Drug Dev"},{"key":"key20220302134039_b111-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.3892\/ijmm.2020.4555","article-title":"A new threat from an old enemy: Re-emergence of coronavirus (Review)","volume":"45","author":"Docea","year":"2020","journal-title":"Int J Mol Med"},{"key":"key20220302134039_b112-ETM-0-0-09693","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3892\/ijmm.2020.4596","article-title":"Towards effective COVID-19 vaccines: Updates, perspectives and challenges (Review)","volume":"46","author":"Calina","year":"2020","journal-title":"Int J Mol Med"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T11:43:47Z","timestamp":1646221427000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2021.9693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,25]]},"references-count":112,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,1,25]]}},"URL":"https:\/\/doi.org\/10.3892\/etm.2021.9693","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,25]]},"article-number":"263"}}